Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study.
Norton TD, Thakur M, Ganguly S, Ali S, Chao J, Waldron A, Xiao J, Patel Y, Turner KC, Davis JD, Irvin SC, Pan C, Atmodjo-Watkins D, Hooper AT, Hamilton JD, Subramaniam D, Bocchini JA, Kowal B, DiCioccio AT, Bhore R, Geba GP, Cox E, Braunstein N, Dakin P, Herman GA. Norton TD, et al. Among authors: dakin p. BMJ Open. 2024 Oct 8;14(10):e087431. doi: 10.1136/bmjopen-2024-087431. BMJ Open. 2024. PMID: 39384241 Free PMC article. Clinical Trial.
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.
Hooper AT, Somersan-Karakaya S, McCarthy SE, Mylonakis E, Ali S, Mei J, Bhore R, Mahmood A, Geba GP, Dakin P, Weinreich DM, Yancopoulos GD, Herman GA, Hamilton JD; COVID-19 Phase 2/3 Hospitalized Trial Team. Hooper AT, et al. Among authors: dakin p. mBio. 2022 Dec 20;13(6):e0169922. doi: 10.1128/mbio.01699-22. Epub 2022 Oct 18. mBio. 2022. PMID: 36255239 Free PMC article. Clinical Trial.
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. Bone HG, et al. Among authors: dakin p. Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523. doi: 10.1016/S2213-8587(17)30138-9. Epub 2017 May 22. Lancet Diabetes Endocrinol. 2017. PMID: 28546097 Clinical Trial.
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C. Silverman SL, et al. Among authors: dakin p. Osteoporos Int. 2015 Jan;26(1):361-72. doi: 10.1007/s00198-014-2871-6. Epub 2014 Sep 19. Osteoporos Int. 2015. PMID: 25236877 Free PMC article.
A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip.
DiMartino SJ, Mei J, Schnitzer TJ, Gao H, Eng S, Winslow C, Ho T, Turner KC, Hassan HE, Patel Y, Davis JD, Trinh N, Manley A, Manvelian G, Fetell M, Braunstein N, Geba GP, Dakin P. DiMartino SJ, et al. Among authors: dakin p. Osteoarthr Cartil Open. 2024 Oct 22;6(4):100533. doi: 10.1016/j.ocarto.2024.100533. eCollection 2024 Dec. Osteoarthr Cartil Open. 2024. PMID: 39554479 Free PMC article.
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM. Bhatt SP, et al. Among authors: dakin p. Respir Med. 2024 Oct 29:107846. doi: 10.1016/j.rmed.2024.107846. Online ahead of print. Respir Med. 2024. PMID: 39481660 Free article.
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS+IMD) in Pediatric Outpatients With COVID-19.
Norton TD, Thakur M, Ganguly S, Ali S, Chao J, Waldron A, Xiao J, Turner KC, Davis JD, Irvin SC, Pan C, Atmodjo D, Hooper AT, Hamilton JD, Hussein M, Subramaniam D, Roque-Guerrero L, Kohli A, Mylonakis E, Geba GP, Cox E, Braunstein N, Dakin P, Kowal B, Bhore R, DiCioccio AT, Hughes D, Herman GA; Trial Investigators. Norton TD, et al. Among authors: dakin p. J Pediatric Infect Dis Soc. 2024 Oct 1:piae105. doi: 10.1093/jpids/piae105. Online ahead of print. J Pediatric Infect Dis Soc. 2024. PMID: 39351798
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.
Isa F, Gonzalez Ortiz AM, Meyer J, Hamilton JD, Olenchock BA, Brackin T, Ganguly S, Forleo-Neto E, Faria L, Heirman I, Marovich M, Hutter J, Polakowski L, Irvin SC, Thakur M, Hooper AT, Baum A, Petro CD, Fakih FA, McElrath MJ, De Rosa SC, Cohen KW, Williams LD, Hellman CA, Odeh AJ, Patel AH, Tomaras GD, Geba GP, Kyratsous CA, Musser B, Yancopoulos GD, Herman GA; Trial Working Group. Isa F, et al. Lancet Infect Dis. 2024 Sep 2:S1473-3099(24)00421-3. doi: 10.1016/S1473-3099(24)00421-3. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39236733
39 results